Obvious importance of TNFRSF12A/TWEAK molecules for the survival of cancers cells prompted the development of the respective targeting agents, which already met initial success in clinical and pre-clinical trials [see Hu et al., 2017, for review]. This evidence concerns the gene TNFRSF12A and cancer.